ThermoTrex
This article was originally published in The Gray Sheet
Executive Summary
Nets $23.1 mil. from public offering of 1.61 mil. shares of common at $15.375, including 210,000 shares sold to underwriters NatWest Securities Limited and Lehman Brothers Inc. under an over-allotment provision. The breast cancer imaging and biopsy systems manufacturer will use the proceeds for "general corporate purposes, including the possible acquisition of one or more businesses," the firm states in a filing with the Securities and Exchange Commission ("The Gray Sheet" March 7, p. 12)